Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - oxycodone hydrochloride, quantity: 80 mg - tablet, modified release - excipient ingredients: polyethylene oxide; magnesium stearate; hypromellose; indigo carmine; hyprolose; polysorbate 80; iron oxide yellow; macrogol 400 - novacodone is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. novacodone modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. novacodone is not indicated as an as-needed-(prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - oxycodone hydrochloride, quantity: 40 mg - tablet, modified release - excipient ingredients: magnesium stearate; polyethylene oxide; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400 - novacodone is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. novacodone modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. novacodone is not indicated as an as-needed-(prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - oxycodone hydrochloride, quantity: 20 mg - tablet, modified release - excipient ingredients: polyethylene oxide; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - novacodone is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. novacodone modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. novacodone is not indicated as an as-needed-(prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - oxycodone hydrochloride, quantity: 10 mg - tablet, modified release - excipient ingredients: magnesium stearate; polyethylene oxide; titanium dioxide; hypromellose; hyprolose; macrogol 400 - novacodone is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. novacodone modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. novacodone is not indicated as an as-needed-(prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 20 mg - tablet, film coated - excipient ingredients: povidone; lactose; magnesium stearate; purified talc; pregelatinised maize starch; titanium dioxide; sunset yellow fcf aluminium lake; polyvinyl alcohol; macrogol 3350; erythrosine aluminium lake - treatment of chronic severe pain of cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 10 mg - tablet, modified release - excipient ingredients: purified talc; lactose; hyetellose; magnesium stearate; cetostearyl alcohol; titanium dioxide; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - ms contin is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms contin is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms contin is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 200 mg - tablet, modified release - excipient ingredients: magnesium stearate; cetostearyl alcohol; hyetellose; purified talc; macrogol 400; titanium dioxide; hypromellose; brilliant blue fcf; quinoline yellow - ms contin is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms contin is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms contin is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 15 mg - tablet, modified release - excipient ingredients: lactose; hyetellose; cetostearyl alcohol; magnesium stearate; purified talc; titanium dioxide; hypromellose; brilliant blue fcf; indigo carmine; quinoline yellow; iron oxide yellow; macrogol 400 - ms contin is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms contin is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms contin is not indicated as an as-needed (prn) analgesia.